TNFSF11 and cancer: In addition, while RANKL monoclonal antibodies showed an anti-bone resorption effect, clinical trials have reported the potential risks of inducing malignant tumors; thus, the drug safety requires further assessment (Goss et al., 2011; Bone et al., 2013; Bone et al., 2017).